

# **Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/C46AD6FB94DEN.html>

Date: October 2018

Pages: 123

Price: US\$ 3,500.00 (Single User License)

ID: C46AD6FB94DEN

## **Abstracts**

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018

### **SUMMARY**

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 33 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Pipeline Review, H2 2018, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and

directs their migration toward sites of inflammation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 4, 5, 2, 1, 15 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Hematological Disorders, Immunology, Ophthalmology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Myasthenia Gravis, Chronic Inflammation, Autoimmune Disorders, Atopic Keratoconjunctivitis, Bullous Pemphigoid, Choroidal Neovascularization, Geographic Atrophy, Intermediate Uveitis, Lupus Nephritis, Neuromyelitis Optica (Devic's Syndrome), Posterior Uveitis, Acute Lung Injury, Age Related Macular Degeneration, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Bacterial Sepsis, Cardiovascular Inflammation, Community Acquired Pneumonia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Glomerulonephritis, Guillain-Barre Syndrome, Hidradenitis Suppurativa, Inflammation, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Polypoidal Choroidal Vasculopathy, Rheumatoid Arthritis, Sepsis, Septic Shock, Subarachnoid Hemorrhage, Traumatic Brain Injury, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Unspecified, Uveitis and Wet (Neovascular/Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects

The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Chugai Pharmaceutical Co Ltd

InflaRx NV

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles

AcPepA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AOND-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bikaciomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cemdisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia

Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mubodina - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nomacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit Complement C5 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101295 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab next generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress



## Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### tesidolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### zilucoplan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### zilucoplan XR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones

### Featured News & Press Releases

Oct 04, 2018: Ophthotech completes patient recruitment as planned for its phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration

Sep 30, 2018: Akari Therapeutics announces new clinical data in post-transplant thrombotic microangiopathies

Sep 28, 2018: Ra Pharma reports positive data from Phase Ib trial of zilucoplan

Sep 24, 2018: Alexion announces successful phase 3 PREVENT Study Of soliris (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Sep 12, 2018: Akari Therapeutics announces new preclinical rheumatoid arthritis data and new clinical data in patients with bullous pemphigoid, highlighting potential advantages of coversin's bifunctional activity inhibiting both the complement and leukotriene inflamma

Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program

Aug 28, 2018: InflaRx To Host R&D Day on Hidradenitis Suppurativa and its

## Breakthrough Anti-C5a Monoclonal Antibody IFX-1

Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US

Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program

Jul 02, 2018: Alexion Pharma Korea's aHUS therapy Soliris gains coverage

Jun 28, 2018: InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis

Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)

Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S.

Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association

Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Products under Development by Companies, H2 2018 (Contd.4), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Akari Therapeutics Plc, H2 2018  
Pipeline by Alexion Pharmaceuticals Inc, H2 2018  
Pipeline by Alnylam Pharmaceuticals Inc, H2 2018  
Pipeline by Amgen Inc, H2 2018  
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018  
Pipeline by InflaRx NV, H2 2018  
Pipeline by ISU ABXIS Co Ltd, H2 2018  
Pipeline by Novartis AG, H2 2018  
Pipeline by NovelMed Therapeutics Inc, H2 2018  
Pipeline by Noxxon Pharma AG, H2 2018  
Pipeline by Ophthotech Corp, H2 2018  
Pipeline by Ra Pharmaceuticals Inc, H2 2018  
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018  
Pipeline by Swedish Orphan Biovitrum AB, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Dormant Products, H2 2018 (Contd.2), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Chugai Pharmaceutical Co Ltd

InflaRx NV

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

## I would like to order

Product name: Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/C46AD6FB94DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C46AD6FB94DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

